Would think so psych, given the low tox of PTX200 at current levels in all data, I see no reason why the FDA would unnecessilary delay recruitment for the AML trial given the urgent need for additional therapies. Possibly slight change to protocols will be required but would think won't be too far off getting underway once again.
Ann: Clinical Trial Update, page-18
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PTX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.8¢ |
Change
-0.001(2.56%) |
Mkt cap ! $30.60M | |||
| Open | High | Low | Value | Volume |
| 3.9¢ | 3.9¢ | 3.8¢ | $47.91K | 1.256M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 881755 | 3.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.9¢ | 150000 | 2 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| PTX (ASX) Chart |